Código QR (código de barras bidimensional)

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

Background Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Pivotal Trial in Melanoma study, which also included patients with distant metastases and d...

ver descrição completa

Na minha lista:
Principais autores: Erika Richtig, Joanna Mangana, Christian Posch, Christoph Hoeller, Julia Maria Ressler, Matthias Karasek, Lukas Koch, Rita Silmbrod, Veronica Aedo-Lopez, Helmut Kehrer, Felix Weihsengruber, Peter Koelblinger, Julian Kofler, Christine Hafner
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2021-02-01
coleção:Journal for ImmunoTherapy of Cancer
Acesso em linha:https://jitc.bmj.com/content/9/2/e001701.full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados